To this end, we used CRISPR-Cas9 technology to delete HOXA13 from BAR-T, a primary monoclonal immortalized cell line derived from metaplastic tissue of a BE patient, with cells expressing both columnar and squamous markers33. The gene discussed is HOXA13; the disease is Barrett esophagus.